Cullinan Oncology, LLC Company Profile

01:43 EDT 16th June 2019 | BioPortfolio

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model. For additional information, please visit

News Articles [587 Associated News Articles listed on BioPortfolio]

Cullinan Oncology grows pipeline through deal with Taiho

Taiho Pharmaceutical Co. Ltd. granted Cullinan Oncology LLC exclusive global rights (excluding Japan) to develop and sell TAS6417 for non-small cell lung cancer.

Cullinan gains EVB-related cancer tx from the Wistar Institute

Cullinan Oncology LLC licensed exclusive global rights to develop and commercialize a candidate discovered by the Wistar Institute for Epstein-Barr virus-associated cancers.

Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology

Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417...Read More... The post Taiho Pharmaceutical...

Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy

Cullinan Oncology is proud to announce that its co-founder and Chief Scientific Officer, Biologics, Patrick Baeuerle, has been honored by the European Molecular Biology Laboratory...

Taiho Pharmaceutical & Cullinan Oncology Establish Collab to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

Taiho Pharmaceutical & Cullinan Oncology Establish Collab to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute

First-in-class small molecule targeting EBV-driven cancers to enter Phase 1 in 2019 Cullinan Oncology, LLC and The Wistar Institute today announced an agreement to acce...

Taiho and Cullinan Enter Cancer Collaboration

Will develop TAS6417, novel EGFR tyrosine kinase inhibitor

Ockham Oncology’s CSO highlights global strength of fully integrated company.

Ockham Oncology’s Chief Scientific Officer Clare Wareing, PhD recounts the companies history and emphasizes complementary strengths that add value following the combination of Ockham Oncology and Ne...

Drugs and Medications [9 Associated Drugs and Medications listed on BioPortfolio]

Neutrexin (trimetrexate glucuronate for injection) [medimmune oncology, inc.]

NEUTREXIN (trimetrexate glucuronate for injection)

Rubraca [clovis oncology, inc.]

These highlights do not include all the information needed to use RUBRACA safely and effectively. See full prescribing information for RUBRACA.RUBRACA (rucaparib) tablets, for oral useInitial U.S. App...

Carboplatin [sagent pharmaceuticals]

Carboplatin Injection(carboplatin aqueous solution)

Carboplatin [meitheal pharmaceuticals inc.]

Carboplatin Injection(carboplatin aqueous solution)

Carboplatin [hospira, inc.]

Carboplatin Injection

PubMed Articles [1397 Associated PubMed Articles listed on BioPortfolio]

Communication training in oncology needs a theoretical framework.

"Neuro-oncology research in Nigeria: a great untapped potential".

Nigeria has the largest population in Africa and has sub-optimal access to neuro-oncology care. It has been estimated that there is approximately 1 neurosurgeon to 2.4 million people in the country, w...

Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Interventional oncology is a subspecialty field of interventional radiology that addresses the diagnosis and treatment of cancer and cancer-related problems by using targeted minimally invasive proced...

Share of Oncology Versus Nononcology Spending in Episodes Defined by the Centers for Medicare & Medicaid Services Oncology Care Model.

Performance-based payments to oncology providers participating in the Centers for Medicare & Medicaid Services (CMS) Oncology Care Model (OCM) are based, in part, on overall spending in 6-month episod...

Cardio-Oncology Fellowship Training and Education.

With the rapid development of novel cancer therapeutics and the growing number of cancer survivors, there is significant demand for cardio-oncology experts to care for these patients. As such, it has ...

Clinical Trials [645 Associated Clinical Trials listed on BioPortfolio]

Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System

The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best che...

Support of the Sexual Health in Oncology

Implementation of sexual health support program in oncology department. This program is organized in 3 axes. One is to inform the side effects of treatment on sexual health. There is a co...

Clinical Concordance Study Between Watson for Oncology and Clinician Practice

At present, Watson for Oncology has been applied in 14 countries worldwide, including China, the United States, Holland, Thailand, India, Korea, Poland, Slovakia and Bangladesh. In a doubl...

Osteopathic Manipulative Treatment in Oncology Patients' Management

The aim of present study was to study the osteopathic manipulative effects on pain relief and quality of life improvement on hospitalized oncology geriatric patients. A non-randomized comp...

Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa

The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to ...

Companies [776 Associated Companies listed on BioPortfolio]

Cullinan Oncology, LLC

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the ...

Takeda Oncology

Takeda Oncology, headquartered in Cambridge, MA, delivers novel medicines to patients with cancer worldwide through its commitment to science, breakthrough innovation and passion ...


OncLive is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary O...

Cold Spring Publishing, LLC

Cold Spring Publishing, LLC, (CSP) is a medical publishing company whose principals have more than 50 years of combined publishing experience, with a specific focus in oncology. CSP publishes JNCCN --...

Michiana Hematology-Oncology,P.C.

Michiana Hematology-Oncology,P.C. is the premier provider of medical oncology, gynecologic oncology and adult hematology services in North-Central Indiana and Southwestern Lower Michigan.Michiana Hema...

More Information about "Cullinan Oncology, LLC" on BioPortfolio

We have published hundreds of Cullinan Oncology, LLC news stories on BioPortfolio along with dozens of Cullinan Oncology, LLC Clinical Trials and PubMed Articles about Cullinan Oncology, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cullinan Oncology, LLC Companies in our database. You can also find out about relevant Cullinan Oncology, LLC Drugs and Medications on this site too.

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Corporate Database Quicklinks

Searches Linking to this Company Record